Psychedelic-Assisted Therapy and The Treatment of Mental Health Conditions with Psychedelics.

I believe that our ability to be strong, healthy, and self-aware is deeply connected to our ability to do good in the world and take care of ourselves and the people around us… And so, I view psychedelics–and more specifically– well-supported psychedelic psychotherapy, as being a wonderfully powerful tool for the kinds of changes we need as a society.

Stacey Wallin

Treating Mental Health with Psychedelics

But what is Psychedelic-Assisted Therapy, and how does it work?

In this post, I search for the reported benefits of psychedelic therapy. I list many of the various psychedelic substances used in psychedelic-assisted therapy and I’ll try my best to explain some of the neurobiological mechanisms that make these psychedelic substances effective for treating some of the most difficult and therapy-resistant mental health disorders.

We will also delve into current research being conducted in Psychedelic-Assisted Therapy, and review some of the ethics, and considerations surrounding this treatment option.

These fascinating new developments in the treatment of mental health issues are very important to me on a personal level and I hope this will be informative for you and will inspire some hope for what the research and their discoveries will do to help many of us, and or our family members with mental health disorders.

So, let’s take a look and see some of what I’ve learned so far in the area of Psychedelic-Assisted Therapy.

What is Psychedelic-Assisted Therapy?

Simply put, psychedelic-assisted therapy is a treatment that involves the use of psychedelic drugs such as LSD, Psilocybin, Ketamine, or MDMA to treat mental health conditions such as major depressive disorder, depression, anxiety, PTSD, and addiction.

Under this therapy, trained professionals supervise patients in a safe and controlled environment.

The therapy helps induce an altered state of consciousness allowing individuals to access their subconscious mind to process repressed emotions or traumas.

Studies have shown promising results for the efficacy of psychedelic-assisted therapy in treating these conditions and its long-lasting positive effects on the mental health of the subjects.

However, it’s important to note that this treatment is not currently legal in all countries and should only be administered by trained professionals in a controlled setting.

Benefits of Psychedelic-Assisted Therapy

Beyond the insights and shifts in perspective that patients describe, part of what makes this field so compelling is that researchers are beginning to understand why these experiences can stick.

The leading explanation is neuroplasticity; the brain’s capacity to form new connections and rewire old patterns. Classic psychedelics appear to give that process a temporary boost, loosening entrenched circuits long enough for healthier patterns to take hold.

In a sense, the experience opens a window, and the brain spends the following days and weeks reorganizing around it.

Psilocybin offers a concrete illustration. Brain-imaging studies have found that it temporarily increases connectivity between networks that normally stay relatively separate; in effect letting regions of the brain “talk” to one another in new ways.

Researchers suspect this loosening of rigid, well-worn pathways is part of how a single experience can produce changes that outlast the drug itself by weeks or months.

It is a fast-moving field drawing serious research interest and real support from the medical community, and it remains one where the treatment isn’t legal everywhere and must happen under proper clinical guidance.

Current Research on Psychedelic-Assisted Therapy

While still experimental, the use of psychedelics in therapy is gaining recognition and support from medical professionals and organizations worldwide.

A number of organizations such as MAPS (Multidisciplinary Association for Psychedelic Studies) and the Johns Hopkins Center for Psychedelics and Consciousness are some of the most well-known leaders in research, education, and advocacy.

This form of therapy has been found to be effective in treating a range of mental health conditions, but more research is needed to fully understand its potential benefits and risks. In a small study of adults with major depression, researchers reported rapid and large reductions in depressive symptoms after two doses of psilocybin given with supportive psychotherapy.

The revival of psychedelic-assisted therapy has sparked interest and investment from major pharmaceutical companies, making it an exciting area of research for the future. With further studies and clinical trials, we may see this innovative form of therapy become a mainstream treatment option for individuals struggling with mental health conditions.

Where psychedelic therapy stands right now (2026)

• Esketamine (Spravato): FDA-approved for treatment-resistant depression — as an add-on since 2019, and as a standalone treatment since 2025. The only psychedelic-adjacent medicine with full FDA approval.
• Psilocybin: Not yet approved, but the furthest along — two positive phase 3 trials (2025–2026) and an FDA review under way. Legally available through state-regulated programs in Oregon and Colorado.
• MDMA: Not approved. The FDA declined it in 2024 and asked for another trial.
• LSD, ayahuasca/DMT, ibogaine: Investigational and in earlier-stage research; not approved, and Schedule I under U.S. federal law.

How Effective is Psychedelic-Assisted Therapy?

So how well does this actually work? The honest answer is that the evidence is genuinely encouraging in specific places — but it’s uneven, and worth understanding rather than flattening into a blanket “it works.”

The format is fairly consistent across studies: a person takes a measured dose of a psychedelic in a calm, controlled setting and spends the session,(often several hours), working alongside one or two trained therapists who help them stay grounded and engage with whatever comes up.

What’s important to understand, is that the drug isn’t the treatment on its own. Most researchers think these substances work by briefly loosening rigid patterns of thought; quieting the brain’s self-focused “default mode” and opening a window of unusual psychological flexibility — in which the real therapeutic work can finally take hold.

The compound lowers the defenses; the therapy does the healing.

That’s also why it can reach places ordinary talk therapy sometimes can’t. People often describe arriving at insights or emotional breakthroughs, around trauma, grief, or long-buried fear — that years of conventional sessions hadn’t unlocked.

The strongest evidence so far is for psilocybin in depression, including treatment-resistant depression, which has now produced positive results in large phase 3 trials, and for MDMA in PTSD, where the trials looked promising.

Athough, the FDA declined to approve MDMA-assisted therapy in 2024 and asked for further study, so it remains investigational rather than available.

None of this makes it a cure-all, and it isn’t something to approach casually or alone: these are powerful experiences, most of the substances involved remain illegal outside approved settings, and they aren’t right for everyone.

But for people who have exhausted the standard options, the results coming out of this field are some of the most hopeful in modern mental-health research, which is why this gets me very excited as a former mental-health care professional myself.

What People Actually Experience in Psychedelic-Assisted Therapy

If the clinical data tells us whether these therapies work, the testimonials tell us what it’s like. 

People who’ve been through psychedelic-assisted therapy tend to describe their sessions in similar terms: a deep emotional openness, a sense of finally being able to face memories or feelings they’d spent years avoiding, and insights that arrive with unusual clarity.

For conditions rooted in trauma, depression, or anxiety, that capacity to move toward the painful material instead of flinching away from it seems to be much of where the healing happens.

Testimonials are subjective, of course, and one powerful experience proves nothing on its own. What’s striking is how often the personal accounts and the controlled research point in the same direction.

Addiction is a good example of how far that’s come. In a 2022 randomized clinical trial published in JAMA Psychiatry(Bogenschutz and colleagues), adults with alcohol use disorder who received psilocybin alongside psychotherapy had significantly fewer heavy-drinking days over the following eight months than those given a placebo; the most rigorous evidence yet that psilocybin may genuinely help with problem drinking.

The Johns Hopkins Center for Psychedelic and Consciousness Research

A lot of the most credible work in this space traces back to one place: the Johns Hopkins Center for Psychedelic and Consciousness Research.

Launched in 2019, it was among the first dedicated centers of its kind in the United States and remains one of the largest, with a team that has spent years studying psilocybin for depression, anxiety, and addiction.

What makes the Center matter isn’t only its output but its rigor: this is mainstream academic medicine taking psychedelics seriously under careful controls, the kind of institutional backing that has helped move these compounds from the cultural fringe back into legitimate clinical science.

None of this makes psychedelic-assisted therapy a finished, one-size-fits-all solution. It’s still an emerging field, it has to happen under trained supervision in a controlled setting, and it won’t be right for everyone.

But between the consistency of the personal accounts and the strength of the newer trials, it’s becoming hard to dismiss and for people the conventional system has failed, that’s no small thing.

Psychedelic Substances Used in Therapy

Psychedelic-assisted psychotherapy is a practice that involves the use of psychedelic substances to treat various mental health conditions.

Some of the commonly used substances that are being researched include Psilocybin, MDMA, LSD, and Ketamine.

These substances are carefully administered in controlled environments under the supervision of trained therapists to ensure optimal results while minimizing risks.

LSD

Lysergic acid diethylamide, more commonly known as LSD, is the compound that, more than any other, gave psychedelics both their scientific promise and their cultural baggage.

It was first synthesized by the Swiss chemist Albert Hofmann in 1938, though he didn’t stumble onto its profound psychoactive effects until 1943. Like psilocybin, it works mainly by stimulating the brain’s serotonin 2A receptors, producing vivid shifts in perception, thought, and the sense of self.

What sets it apart in practical terms is duration: an LSD session can run eight to twelve hours, which is far longer than psilocybin. This difference also shapes how, and how often, it can realistically be used in a therapeutic setting.

What many don’t know is that LSD was a serious research subject long before it became a counterculture symbol. Through the 1950s and ’60s it was studied in thousands of patients, perhaps most notably for alcoholism. A meta-analysis of those mid-century trials found that even a single dose was associated with reduced problem drinking. That work largely stopped when LSD was placed in Schedule I in 1970, freezing clinical research for decades.

However, that research after many years is now thawing.

Carefully controlled modern trials have begun re-examining LSD for anxiety; including the anxiety that accompanies a life-threatening illness and a standardized pharmaceutical form has advanced into trials for generalized anxiety disorder.

Microdosing, the popular practice of taking sub-perceptual doses for mood or focus, draws a great deal of attention, but although there is a lot of hype surrounding this practice; the more rigorous placebo-controlled studies have so far struggled to show benefits beyond what expectation alone produces.

Taken together, LSD remains one of the most studied yet most misunderstood of these compounds; a substance whose therapeutic potential is finally being rediscovered with the rigor it should have had all along.

Psilocybin

Psilocybin is a naturally occurring psychedelic substance found in certain types of mushrooms. Recent research has shown that psilocybin-assisted therapy can be effective in treating mental health conditions such as depression, anxiety, addiction, and PTSD (Post Traumatic Stress Disorder).

The effects of psilocybin can alter perception, mood, and thought patterns, leading to introspection and a sense of connection to the world. It is important to note that psilocybin should only be used under the guidance of a trained professional in a controlled environment.

Studies have shown that psilocybin may have several potential therapeutic uses, including increasing feelings of empathy, spiritual connection, and creativity while reducing symptoms of anxiety and depression.

A milestone study conducted by Johns Hopkins Medicine researchers in 2022 showed that psilocybin treatment for major depression may be effective for up to a year after treatment.

Similarly, a study from 2014 reported that a small number of longtime smokers were able to quit the habit after using psilocybin in a carefully controlled and monitored setting.

Ketamine

Ketamine occupies an unusual place in this field: it’s the one substance here that’s already a fixture of mainstream medicine.

A dissociative anesthetic in clinical use since the 1970s, it produces altered perception, a sense of detachment from the body, and at lower doses a kind of relaxed euphoria; the same properties that, in a controlled setting, seem to open a therapeutic window.

What sets ketamine apart from conventional antidepressants is speed. Where SSRIs can take weeks to work, ketamine often eases depression and acute suicidal thinking within hours; difference that matters enormously in a crisis.

It also works along a different pathway, acting on the brain’s glutamate system rather than serotonin, which may be why it can reach people who haven’t responded to standard medications.

It’s worth being precise about its status, because “ketamine” and the FDA-approved treatment aren’t quite the same thing. Ketamine itself is approved as an anesthetic, and its intravenous use for depression is off-label.

The form the FDA has actually approved for depression is esketamine — a nasal spray derived from ketamine and sold as Spravato — cleared in 2019 for use alongside an oral antidepressant and, since 2025, as a standalone treatment for treatment-resistant depression.

Because of its dissociative effects, it’s given under medical supervision in a certified setting, not taken at home.

The relief is real but not always lasting: benefits may hold for days to weeks, repeat sessions are common, and the long-term effects of repeated use are still being studied. Even still, ketamine has become the clearest proof yet that one of these compounds can earn a legitimate, regulated place in psychiatric care.

MDMA

Although MDMA is the same compound sold on the street as ecstasy or molly, the clinical version is pure and precisely dosed, unlike the impure mix which is sold recreationally.

It has been studied less as a classic psychedelic and more as an “empathogen”: a substance that lowers fear and defensiveness while heightening trust, empathy, and emotional openness.

That particular combination is what made it such a compelling candidate for treating post-traumatic stress disorder.

The logic is straightforward. PTSD often traps people in avoidance where memories are can be too threatening to approach, which is exactly what keeps them unresolved.

By quieting the brain’s fear response and softening emotional guardedness, MDMA appears to open a window in which patients can revisit and process traumatic memories alongside a therapist without being overwhelmed.

It isn’t the drug alone doing the work; it’s the drug making the therapy possible.

For a while, MDMA-assisted therapy looked like the frontrunner to become the first treatment of its kind approved in the United States. It earned the FDA’s Breakthrough Therapy designation in 2017, and two phase 3 trials reported significantly greater reductions in PTSD symptoms among patients who received MDMA than among those given a placebo.

But this is where the story turned, and it’s important to note; in June 2024, an independent FDA advisory committee voted overwhelmingly against the treatment, citing problems hard to dismiss: a “functional unblinding” issue.

MDMA’s effects were so obvious that patients and therapists could usually tell who had received it, which can skew results. besides the gaps in safety data and concerns about how the trials were run.

In August 2024 the FDA formally declined to approve it and asked the sponsor, Lykos Therapeutics, (formerly MAPS Public Benefit Corp.) to conduct another phase 3 trial.

Soon after, a journal retracted three earlier MDMA papers over data-integrity concerns, and Lykos laid off much of its staff.

So where does that leave us?

MDMA’s underlying promise for trauma hasn’t evaporated; the symptom reductions in those trials were real, and research continues.

But as of 2026 it remains investigational, not an approved or legally available treatment, and its path forward now runs through the slower, more rigorous work the FDA has demanded.

MDMA-Assisted-Psychotherapy Treatment Manual (MAPS)

Cannabis

Cannabis is another substance that has been gaining attention for its potential in treating mental health conditions. Specifically, CBD (cannabidiol), a non-psychoactive compound found in cannabis, has been studied for its effects on anxiety and depression. It works by interacting with the body’s endocannabinoid system, which regulates mood and stress response.

However, it is important to note that while CBD does not produce the “high” associated with THC (tetrahydrocannabinol), it still has potential risks and can interact with other medications. As such, it should only be used under the guidance of a medical professional.

Ayahuasca

Ayahuasca is a bitter brew that Indigenous peoples of the Amazon have prepared for centuries for healing and spiritual ceremony.

What makes ayahuasca work is a genuinely clever bit of plant chemistry.

One plant, known as chacruna, supplies the DMT, the powerful psychedelic that does the heavy lifting. The other, the Banisteriopsis caapi vine, plays a quieter but essential role:

It switches off the stomach enzymes that would otherwise digest that DMT before it could ever reach your brain.

Together they produce an hours-long experience that acts on the brain’s serotonin (5-HT2A) receptors, usually alongside intense emotion, deep introspection, and the purging that many traditions regard as part of the cleansing itself.

Researchers have taken notice for good reason. In a 2019 randomized, placebo-controlled trial, a single dose of ayahuasca produced significant, rapid improvement in people with treatment-resistant depression — early but striking evidence that has helped carry the brew from ceremony toward the clinic, with further study of depression, anxiety, and addiction now underway.

The cautions here are specific, not generic. The very MAO-inhibiting compounds that make ayahuasca work also make it genuinely hazardous to combine with many common medications — especially SSRI and SNRI antidepressants, where the interaction can trigger a dangerous reaction called serotonin syndrome.

It also raises blood pressure and heart rate in ways that matter for anyone with a cardiovascular condition, and in the United States the DMT it contains is illegal (Schedule I), with narrow exemptions granted to a few religious organizations. For all of those reasons, ayahuasca should only ever be approached with experienced, responsible facilitation and full medical screening.

None of that erases its promise. For some people who have exhausted conventional options, ayahuasca seems to open a door that nothing else has — but it’s a door to walk through carefully, well-informed, and never alone.

Ibogaine

Ibogaine sits at the more intense and more cautionary end of this spectrum.

It’s a compound found in the root bark of the iboga shrub, native to West Central Africa, where it has long played a role in traditional spiritual and initiatory ceremonies. What’s drawn modern researchers to it is a striking and unusual property: its apparent ability to interrupt addiction, particularly addiction to opioids.

Ibogaine seems to work on two fronts at once. It acts on the brain systems that drive craving and dependence.

Many users report that it sharply reduces withdrawal symptoms; while also producing a long, dreamlike, deeply introspective state in which people often revisit and confront the emotional wounds underlying their substance use. That combination of a pharmacological reset and a psychological reckoning is what makes it so intriguing as a possible addiction treatment, and there’s early interest in its antidepressant potential as well.

But ibogaine demands real caution, and not in a generic way.

It can affect the heart’s rhythm in genuinely dangerous ways; it has been linked to serious cardiac events and deaths, often when taken without medical screening or monitoring. — This is why it should never be approached casually or alone. Any legitimate use belongs within a comprehensive treatment plan, under trained medical supervision with proper cardiac screening.

Psychedelic-assisted therapy as a whole is still controversial and not yet embraced by mainstream medicine. But for people trapped in addiction or treatment-resistant suffering; and who have often already tried everything the conventional system offers — the results emerging from this research are too significant to ignore.

Neurobiological Mechanisms of Psychedelic-Assisted Therapy

A common question is, “What’s actually happening in the brain?”

It helps to think in three layers:

• What these compounds do at the level of receptors.
• What that does to the brain’s networks.
• What lingers afterward.

How do psychedelics work in the brain?

The classic psychedelics; psilocybin, LSD, and DMT all share a key mechanism: they’re agonists at the brain’s serotonin 2A (5-HT2A) receptors.

Stimulating those receptors sets off the cascade that produces the altered state.

(Not everything here works this way: ketamine acts on the glutamate system as an NMDA-receptor antagonist, and MDMA floods the brain with serotonin and oxytocin different areas yet in an overlapping space.)

At the level of networks, that receptor activity does something striking. It quiets the default mode network — the regions tied to our sense of a fixed, narrating self, and to rumination; while increasing communication between networks that normally keep to themselves.

For a few hours the brain becomes more interconnected and less rigidly organized. That loosening is thought to underlie both the dissolving sense of self people describe and the chance to step outside well-worn mental ruts. 

Neuroplasticity and its Role in Psychedelic-Assisted Therapy

That explains the experience — but not why a single session can keep paying off weeks later.

The leading answer is neuroplasticity. In laboratory and animal studies, classic psychedelics have
been shown to promote structural plasticity: the growth of new dendritic spines and synapses in
the cortex, driven by 5-HT2A, TrkB, and mTOR signaling.

In the same pathway behind ketamine’s rapid antidepressant effect. This matters because depression and chronic stress tend to do the opposite, eroding those very connections in regions that govern mood and decision-making.

Psychedelics, in effect, may help the brain rebuild where stress has worn it down.

There are two things here that are important to note in regard to this.

Most of this direct evidence so far comes from rodents and cell cultures; confirming the same in humans is an active, unfinished area of research.

And plasticity isn’t automatically good; an unusually malleable brain is also a vulnerable one, which is exactly why what happens around the experience matters so much.

Many researchers now conceptualize a window of heightened plasticity that opens after a session: a stretch of days or weeks when the brain is unusually ready to form new patterns.

What gets planted during this window is where therapy comes in.

Integrating Psychedelic-Assisted Therapy with Traditional Therapy

Psychedelic-assisted therapy can be integrated with traditional talk therapy to enhance the effectiveness of treatment for mental health conditions.

While traditional therapy helps patients process and integrate their experiences, psychedelic-assisted therapy can help patients access deeper emotions and insights that may be difficult to achieve through traditional therapy alone.

Integration sessions with a therapist after a psychedelic experience can help patients apply insights gained from the experience to daily life.

Combining different modalities of therapy can also provide a more holistic approach to mental health treatment. By integrating psychedelic-assisted therapy with traditional talk therapy, patients have access to a more comprehensive approach, addressing both conscious and unconscious aspects of themselves.

Combining psychedelics with talk therapy or cognitive behavioral therapy

In practice, treatment is built around three phases. 

• Preparation comes first — several sessions to build trust, set intentions, and get ready for what may surface.
• Then the dosing session itself, where the work is mostly experiential.
• Finally, and arguably most important, integration which are the sessions afterward where insights get translated into real changes in how a person thinks and lives.

This is where pairing psychedelics with talk therapy or CBT is most beneficial. The experience tends to surface buried material and loosen fixed beliefs; the therapy is what turns that raw material into durable change; ideally during the plasticity window, when the brain is most receptive.

On its own, a powerful experience can fade into a memorable story. Anchored by skilled therapy, it can become a turning point.

The role of the therapist in psychedelic-assisted therapy

The therapist’s job here looks different from ordinary practice.

During the session itself they mostly hold space; meaning they keep the person physically and emotionally safe, offering reassurance, and resisting the urge to steer, trusting the process to go where it needs to.

Around that they work to build trust beforehand and guide integration afterward.

That relationship isn’t incidental to the treatment; it’s part of how it works. A sense of safety shapes the experience as much as the dose does, which is why practitioners need specialized training, and why “set and setting” — a person’s mindset and their surroundings is treated as seriously as the pharmacology.

Ethics and Considerations for Psychedelic-Assisted Therapy

For all the promise, this is a powerful intervention with real risks, and using it responsibly
rests on a few non-negotiables: it has to be legal, the right person has to be screened in, the
setting has to be safe, and consent has to be genuine.

Legality and Regulations of Psychedelic-Assisted Therapy

The legal picture is patchwork and shifting.

In the U.S., most classic psychedelics remain
Schedule I at the federal level, even as exceptions open up: esketamine is FDA-approved, Oregon
and Colorado have launched state-regulated psilocybin programs, and certain churches hold
religious exemptions for ayahuasca.

Elsewhere, the rules vary widely by country. (For a current
snapshot of where each substance stands, see the 2026 status box earlier in this article.)

The short version: legality depends heavily on where you are and which substance is involved; so
it’s worth checking current local law rather than assuming.

Safety Concerns and Precautions for Psychedelics

Psychedelic-assisted therapy is a treatment that should only be administered by trained professionals in a controlled and safe environment.

Not everyone is a candidate, and it is necessary for patients to undergo a thorough screening process to ensure they are suitable candidates for the treatment; A personal or family history of psychosis or bipolar disorder is generally a reason for caution with classic psychedelics, and specific substances carry specific risks worth screening for.

As mentioned earlier, the dangerous interaction between ayahuasca’s MAOIs and SSRI antidepressants, or
ibogaine’s effects on heart rhythm, are two reasons.

Also, dose and duration need to be controlled to limit difficult reactions like acute anxiety or, rarely, psychosis.

Furthermore, none of this is a first-line treatment; it belongs further down the road, for people who haven’t found relief in standard care.

Informed consent and patient screening for psychedelic-assisted therapy

When it comes to psychedelic-assisted therapy, there are several important ethics and considerations that need to be taken into account.

Beyond medical fit, the ethics rest on genuine informed consent. A person should understand the
risks, the benefits, and the sheer unpredictability of the experience before agreeing to it.

This understanding includes:

• No coercion or pressure
• Clear confidentiality
• Having respect for the cultural and spiritual traditions many of these medicines come from.

Because participants are unusually open and suggestible during a session, the responsibility on the practitioner to be trained, ethical, and trustworthy is even higher than in ordinary therapy, not lower.

The importance of setting and preparation in psychedelic-assisted therapy.

Finally, set and setting.

The same dose can produce wildly different experiences depending on a person’s state of mind going in (set) and the environment they’re in; which is why preparation and a calm, safe, supportive space (setting) aren’t niceties but part of the treatment itself.

A trusted guide, a comfortable room, a clear intention: these quietly shape outcomes, lowering the odds of a
frightening experience and raising the odds of a meaningful one.

It’s the least pharmacological part of the whole process, and one of the most important.

In addition to these considerations, it’s important to note that the environment in which the therapy takes place can also have a significant impact on its effectiveness.

Creating a comfortable, supportive setting can help patients feel more at ease during their sessions and increase the likelihood of positive outcomes.

My Final Thoughts

Psychedelic-Assisted Therapy is a promising new approach to treating mental health conditions that have been resistant to traditional therapies.

As for me, I have had a few experiences with psychedelic substances, specifically Ayahuasca on two ceremonious occasions and Psilocybin three times without formal assisted therapy. However, each event was planned intentionally for therapeutic introspection while experienced in a safe environment.

After each of my psilocybin experiences, I had some informal integration immediately after and over a course of several days with my wife who is a Licensed Psychologist.(Dr. Betina De Souza Psy.D)

With Ayahuasca, I had a much more intense and serious experience, During the Ayuhuasca ceremony, deep personal insights and revelations were brought to light. Ideas about my own insecurities and relationships with many significant people from my past and also my father who has since passed away.

Many speak of the hallucinations they experience but those were only minimal for me, however, I experienced very strong feelings of love and gratitude that are hard to explain.

The therapeutic and residual effects of my experience with what I consider a sacred plant medicine lasted with me for weeks, possibly even months later.

Because of my own experiences with these plant medicines, I can definitely, see the potential for healing in anyone who is open to it and able.

Although it is not for everyone, I can say that my experiences with psychedelics have been positive.

By far, some of the most eye-opening, life-changing, perspective-shifting, and significant experiences of my life!

Frequently Asked Questions

If you or someone you know is struggling with a mental health condition, talk to your healthcare provider about whether Psychedelic-Assisted Therapy may be a viable treatment option for you.

And please do your research. I’ve provided many links to resources where you can learn more.

Useful Links and Resources

Psychedelic Therapy Directories

Provider Network – Premier Psychedelic Support

Psychedelic Directory – Courses, Retreats, Clinics

Integration Therapists for Past Psychedelic Experiences

Psychedelic Integration List – MAPS

Links to Organizations that Support Psychedelic Research

MAPS – Multidisciplinary Association for Psychedelic Studies

The Johns Hopkins Center for Psychedelics and Consciousness

Center for Psychedelic Research 

Erowid

International Center for Ethnobotanical Education Research and Service (ICEERS)

Zendo Project

Related Videos/Documentaries

Psychedelics and Medicine

Can Psychedelics Cure?

Psychedelica (Series also available on GAIA app)

Join Amazon Prime – Watch Thousands of Movies & TV Shows Anytime – Start Free Trial Now Try Audible Premium Plus and Get Up to Two Free Audiobooks

References

_{^{Disclosure: The informational content posted here is based on research and personal experience. I do not have any sponsors and I am not compensated for my reviews or opinions. However, this post may contain affiliate links. If you click on an advertisement or product and continue to make a purchase, I may receive a referral commission. Also, as an Amazon Associate, I earn from qualifying purchases.”}}